Roth Capital Trims Viking Therapeutics (NASDAQ:VKTX) Target Price to $15.00

Viking Therapeutics (NASDAQ:VKTX – Get Rating) had its price objective cut by investment analysts at Roth Capital from $20.00 to $15.00 in a research report issued on Thursday, The Fly reports.

Several other research analysts also recently weighed in on the stock. StockNews.com assumed coverage on shares of Viking Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research downgraded shares of Viking Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 7th. Finally, Raymond James decreased their price target on shares of Viking Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, February 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $14.31.

Viking Therapeutics stock opened at $2.20 on Thursday. The stock’s 50 day simple moving average is $3.04 and its two-hundred day simple moving average is $4.28. The stock has a market cap of $170.22 million, a price-to-earnings ratio of -3.06 and a beta of 1.67. Viking Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $7.20.

Viking Therapeutics (NASDAQ:VKTX – Get Rating) last posted its earnings results on Wednesday, April 27th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). During the same period last year, the company earned ($0.19) EPS. As a group, equities analysts forecast that Viking Therapeutics will post -0.86 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Lindbrook Capital LLC raised its position in shares of Viking Therapeutics by 1,062.8% during the 4th quarter. Lindbrook Capital LLC now owns 7,500 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 6,855 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Viking Therapeutics during the 4th quarter valued at about $38,000. Qube Research & Technologies Ltd purchased a new stake in shares of Viking Therapeutics during the 4th quarter valued at about $51,000. Fox Run Management L.L.C. purchased a new stake in shares of Viking Therapeutics during the 4th quarter valued at about $52,000. Finally, Virtu Financial LLC purchased a new stake in Viking Therapeutics in the 4th quarter worth about $58,000. Hedge funds and other institutional investors own 46.05% of the company’s stock.

Viking Therapeutics Company Profile (Get Rating)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

See Also